By Sven Larsen (@svenplarsen)

Watching the big game last night,  I was struck by the diversity of products being advertised. Domain name registration and e-trading as well as the old reliables like packaged goods and automobiles. But one category was conspicuous by it’s absence. Where were the Pharma Superbowl ads?

It’s not like big Pharma companies don’t have the marketing budget for a Superbowl spot. And Pharma agencies certainly have the talent to pull off something as compelling as bungee jumping cars or Danica Patrick in a jumpsuit. So why no creative or splashy spot advertising a big name OTC or prescription product?

I can understand not wanting to spend the money on giving over half an uber expensive Superbowl spot to Fair Balance. But I also think it’s indicative of the way we sometimes approach Pharma marketing.

Pharma agencies have struggled for years with the perception that healthcare marketing is a “creative ghetto”, a place where fresh and original ideas are smothered by regulatory review and conservative clients. Of course, anyone who has been to the Mannys or spent any time in the industry knows this isn’t true. But, at times, I think we do suffer from an inferiority complex. A belief that spots like “1984″ are for cool, hip brands like Apple and not for boring old Pharma.

It’s an attitude we need to shake off. Whether it’s digital media, social marketing or more traditional outlets like television and print, Pharma needs to stand toe to toe with any other type of product and service and we need to use all the weapons in the marketing arsenal. Because, at the end of the day, our message is just as (if not more) important than Coke or Toyota’s. What car you drive or what soda you drink may enhance your life. But what drug you take or what healthcare behavior you modify may save it.

And if the message is that important, isn’t it time we got as creative as possible when it comes to spreading it?

by Jason Brandt (@jasondmg3)

Mad Men protagonist Don Draper works in the show’s fictional advertising agency, but the challenges he faces are real, and not much different than what many healthcare marketers face on a daily basis – meeting deadlines, incorporating new technologies, managing perceptions, and influencing behaviors all while ensuring personal growth.

The pharmaceutical industry and Mad Men’s advertising world have a lot in common: both include vibrant and competitive industries, have major players that influence standards and rely on a targeted audience to boost their business. What can pharma learn from Mad Men?

The devil is in the details. Producer Mathew Weiner pays meticulous attention to every detail from casting to the story line as well as ensuring the props and the set accurately reflects the time period. Creating an authentic and engaging experience with every dialog, interaction and visual is why fans flock to the three-time Emmy Award-winning series. Pharmaceutical companies looking to create that same level of customer loyalty should incorporate that same attention to detail, whether that’s using an authentic voice when communicating on social networks, creating intuitive, customer-friendly applications and services or delivering outstanding customer experiences.

Pick a job and then become the person that does it. Bobbie Barrett delivered this little pearl over cocktails with ex-lover Don Draper. Explaining how she became her husband’s manager – a man who wouldn’t have a career without his wife’s revealing bust line and shrewd wheeling and dealing – she tells him she invented the job.

Ten years ago there was no need for an HTML5 programmer, social media strategist or elder care services coordinator – those jobs didn’t exist. With technology and increased access to information changing everything, companies need to have their pulse on what skills will be needed in the future and recruit a workforce with the right skills to support growth. Individuals also need to develop skills that continue to add value and take control of their internal career path.

Don’t overlook the value of reinventing yourself. Don Draper is a chameleon. Born Dick Whitman, he’s no stranger to reinventing himself, whether it’s changing his name or leaving an established New York advertising agency to launch a start up.

Pharmaceutical companies may find themselves needing a reinvention with the expiration of drug patents expected to affect drug pricing, marketing and patient usage. Surviving patent expiration will require pharmaceutical companies to refocus their marketing messages to ensure they don’t lose significant market share to generic competitors. Shifting the strategy from brand loyalty to one that includes a more life-cycle branding and consumer education emphasis can deliver a competitive edge.
If you don’t like what’s being said, change the conversation. When a New York City developer didn’t like how he was being treated in the press, Don Draper suggested changing the conversation.

Brand management today is a two-way engagement with consumers often having louder share of voice than company-issued messaging. Putting processes in place to monitor online conversations is no longer a nice-to-have but a business necessity. Before things go south, develop strategies for how you’ll respond to negative or inaccurate information. Changing the conversation doesn’t necessarily require hijacking a thread, but paying attention to what is being said and offering truthful information can help consumers maintain a positive perception of your brand.

While we may not wear the narrow ties or hair pomade of Don Draper, we can still follow in his footsteps by keeping track of the details, owning the conversation and being unafraid to innovate when reinvention is the best option.

Like my image? You can get yourself one over at Sterling Cooper.

by Jason Brandt (@jasondmg3)

Can two of the hottest organizational and operational trends from the last 20 years – Lean Manufacturing and Six Sigma – be adapted to pharma? That’s a trick question: They already have been, and quite successfully.

But, how about online pharma marketing? It’s a more interesting proposition.

First, some definitions for the majority of us who aren’t steeped in business-optimization methodologies: There are differences between Lean and Six Sigma methods of business, but both emphasize continuous improvement and a formal process of review and correction. Lean is sometimes seen as less time-consuming than Six Sigma; the easiest way to boil it down is that Six Sigma seeks reduced process variation, and Lean strives for improved process flow.

All of which sounds great if you’re running a manufacturing facility – who wouldn’t want fewer variations from an optimized process or an improved process flow? And they’re proven: Top-flight Six Sigma implementation is one of the factors that helped General Electric become a leader across many industries.

Applying these principles to digital pharma marketing isn’t quite the stretch you’d imagine. And while implementing a full Lean or Six Sigma strategy in your marketing efforts requires more than a lone blog entry for guidance, you can grasp some of the broad brush strokes pretty quickly:

Get good at measuring, and then measure everything. Whether you’re drawn to the Lean or Six Sigma model – and there’s a case to be made for both when it comes to pharma marketing – you’ll want to figure out how to measure things, both more comprehensively and more accurately.

Anyone exposed to social media or Web analytics knows you can measure online activity, but don’t be lulled into a false sense of security by these easy numbers. The sort of comprehensive measurement that these processes call for cover things like median and mean sales growth per sales rep in the weeks following an advertising campaign’s launch, or ROI per dollar spent on paid media in category-leading drugs (which might have much higher public awareness) versus secondary drugs.

Bottom line: You can’t track what you can’t measure and you can’t improve what you can’t track.

Round up your black belts. Six Sigma relies heavily on small groups of professionals, sometimes called black belts or green belts, empowered to review data, brainstorm improvements and then implement them. They operate with management’s approval, but they are also empowered to suggest changes outside of their department or division if that’s what it takes to improve quality.

Note a couple of key differences from many marketing processes: First, there’s an understanding that solving a problem might mean changes outside of the department or area of business operation – a big change for some marketing operations. Second and equally important is the idea of the small force of change agents, something that is necessary for breaking down organizational silos and stimulating overall movement of social initiatives.

Bottom line: Even if an organization’s social media strategy is centralized, training the entire organization can mistake-proof social execution.

Commitment to the process matters more than implementing it everywhere. Make no mistake: It’s a huge commitment to undertake either Lean or Six Sigma methodologies. That’s why it’s acceptable – advisable, even – to dip your organizational toe into the water slowly, with project-level and department level test projects. Try, fail, analyze, iterate and try again – get the process right for your team and your challenges, and then you can roll it out to more of your digital marketing efforts.

Bottom line: Every business is different. As new technologies, platforms and devices expand the digital experience, flexibility is necessary for managing a fast-moving, changing environment.

Marketing has always been a simple proposition: Deliver value in order to capture value. Within that context, business-optimization regimens like Lean and Six Sigma not only have a place in digital marketing, they’re just one more step in a long tradition of figuring out the most effective, efficient way to get the right value proposition into the right prospect’s hands so they can take action.

We’ve been writing a lot about the case for mobile in healthcare over the past couple of years. And we’re going to keep writing about it. With one quarter of US adults turning to their mobiles for healthcare information, it’s important that the industry keeps pushing forward with innovative sites, apps and tools that will keep us at the top of our game and, in the end, be useful to the community at large.

To that end, exploring how to better accomplish this is always something we’re interested in. Which is why, on Thursday, January 26^th, some of the crew from Pixels & Pills will be at the BDI Mobile Healthcare Communications 2012 Case Studies and Roundtables.

About the Event:
Consumers and professionals are increasingly using their mobile devices for healthcare information. They are also interacting with healthcare providers and colleagues on their mobile phones. This conference will demonstrate the best case studies of how major healthcare brands are connecting with consumers and professionals through mobile communications.

Speakers and Roundtable Moderators:
Meighan Berberich, Vice President, Marketing, BlogTalkRadio
Lance Hill, CEO, Within3
Scott Hopkins, Executive Vice President, Anderson Direct Marketing
Monique Levy, Vice President, Research, Manhattan Research
Dr. Katherine Malbon, Assistant Professor of Pediatrics, Division of Adolescent Medicine, Mount Sinai Hospital
Talya Miron-Shatz, PhD, Marketing Department, Wharton, University of Pennsylvania
Jenna Mons, Consumer Product Manager for LAP-BAND®, Allergan
Mario Nacinovich, Jr., Editor-in-Chief, Journal of Communication in Healthcare; Managing Director, AXON
Xavier Petit, Shire
John Vieira, Daiichi-Sankyo
Date: Thursday, January 26, 2012
Time: 8:00 a.m. – 1:00 p.m.
Place: The Graduate Center of The City University of NY; 365 5th Ave; NY, NY 10016

For additional information, including registration, please click here to visit the event website. Use promo code P&P for a discounted rate of $175.

Hotel Sponsor: Hotel 373 is the official hotel of BDI’s events. Click here to receive a discounted rate

Sponsors:
PR Newswire; Within3; Anderson Direct Marketing; BioCrowd ; Cinchcast; Journal of Communication in Healthcare; Manhattan Research; New York University; Pixels and Pills; Public Relations Society of America – New York Chapter; Society for Healthcare Strategy and Market Development

Last week Pixels & Pills’ editor Briana Campbell had the pleasure of sitting down for a Skype chat (so the quality is a little lower than our normal, professional videos) with Dr. Darshan Kulkarni (@FDALawyers) of the Kulkarni Law Firm in Philadelphia. And while the questions answered in the conversation don’t constitute legal advice and should not be constructed as such, we were very happy to get the thoughts of a lawyer on the recent FDA draft guidance. And to have him address some questions that you all had put forth on Twitter.

Further information on some of the things Darshan touches on can be found in the following sources:

The Park Doctrine

Par Pharmaceutical versus the FDA

FDA’s Cease and Desist to Triple Flu Defense

One more time, Jonathan Richman’s handy flow chart

He also mentioned to us, after we’d turend the camera off, that the FDA uses draft guidance as a way to express their thoughts on certain issues without the rigor of regulations. There is much draft guidance out there that never becomes finalized. To us, this means that we should take the guidance for what it is – all we are getting on emerging electronic/social media platforms at this time. And maybe ever.

Do you have questions for Dr. Kulkarni? Thoughts on this conversation? Leave them in the comments and we’ll continue the discourse.

By Sven Larsen

These days everyone is familiar with e-commerce. And our more social media savvy readers are probably all clued up on f-commerce (that’s Facebook commerce folks). I’ve even heard Google’s Adwords and Adsense business referred to as g-commerce. But what about the next letter in the alphabet. How come no one is talking about h-commerce?

Make no mistake; healthcare commerce online is big business (A Forrester research report projects 2012 Healthcare spending online will reach $8.7 billion). And the traffic for online health retailers is pretty impressive, too. Drugstore.com, a pioneer in the space nets 4.66 million unique users a month (and a not too shabby $416 mm a year in annual sales). But their traffic pales next to more traditional drug retailers like CVS (6.37 mm uniques per month) and Walgreen’s (10.6 mm uniques per month). And then, of course, there is the 800-pound gorilla of health info online, Web MD with a whopping 16 million unique visitors per month (to put that number in comparison, the New York Times website average 17 mm uniques per month). It’s clear that Americans are more than comfortable obtaining health information online and they’re also comfortable with online purchasing of the drugs and other healthcare products they need. So why aren’t we doing a better job of selling those products to them?

Don’t get me wrong. I’m not advocating digital snake oil sales or anything similarly distasteful (or anything that might get anyone in trouble with the FDA). In fact, quite the opposite. As an industry, it’s a real black eye for us that most people associate online drug information with spam e-mails offering cheap Viagra and that most of the discussion of drug sales online revolve around things like obtaining cheap Canadian pharmaceuticals. No wonder the Pharma industry has such a bad reputation with many consumers. While drug manufacturers have sat in their ivory towers doing their best to ignore conversations with consumers, the digital space has been ceded to shady characters who have no interest in preserving brand integrity or serving patient’s needs.

Yes, we’re bound by strict regulatory requirements that preclude us using some of the traditional methods that other consumer marketers use to tout the features and benefits of their products. But that doesn’t mean that we can’t find new and better ways to educate consumers about their health and help them maintain positive lifestyles. Or even just make their lives a little easier.

Consider the plight of a young mother who has just relocated with her family to a city where she doesn’t know anyone. She needs to find a GP she can trust for her family. She needs to find a pharmacist she can trust as well. Maybe one of her children has special needs and she needs to find a local support group. Maybe she just needs to know where that 24-hour drugstore is located. Perhaps she has a prescription that has run out and no one to authorize a refill. What does she do now?

She probably looks at Yelp or one of the many sites that publish HCP reviews. She may type the name of a national drugstore chain into a search engine and find a store at random. And she will spend a lot of time online looking for resources to help her and her family. Not a problem, right? We all know young moms have nothing but time on their hands.

How much better would it be if she were able to go to a one stop portal that contained tons of information about the healthcare resources available in her community? A site that listed HCPs, local specialists, pharmacists and patient support groups. A site that also provided links to educational resources online and e-commerce partners who could help with issues of supply and cost. A site sponsored by one (or several) Pharma companies that provided a real service to the community and a positive representation of our industry online. And, not for nothing, a site that increased compliance and by extension benefitted both the patient and the Pharma company.

The above, is just one example, of ways we can interact with and benefit the end consumer, without violating FDA guidelines. I’m sure our readers could come up with numerous other ideas. The key here is to once again step outside the narrow confines of our traditional industry thinking and to learn from other players in the market. A good start would be for Pharma companies to become more active in the general conversations about online marketing and retailing that take place at sites like INTERNET RETAILER and SHOP.ORG. Ultimately, the end consumer for Pharma is a consumer and we need to realize that despite all the rules that bind us, the purchase funnel for our products is no different than any other.

What do you think? Is this the year we finally start talking about h-commerce?

We recently chatted with Paul Simms, Chairman of eyeforpharma, the mastermind behind the ‘Pharmasuiticus reps’ YouTube nature “documentary,” which you may have seen doing the rounds in your social networks.

Pixels&Pills: Why did you decide to make this video?

Paul Simms: We find ourselves quite frustrated with the current situation in pharmaceutical sales management. This is still the area of highest expenditure in medical promotion, and whilst we have seen some movement, there is still a hardcore group resisting the new methods which will ultimately make a great improvement to healthcare at large. This is despite the swathes of industry insiders preaching the need for change. So, to really incite action, we simply went to great lengths to emphasise the ridiculous nature of the once-saturated pharma sales landscape.

P&P: Has it worked?

PS: Depends what you mean.  After a week, there were over 5,000 views without us any real promotion from us, and we’re currently close to 10,000 views, so people are obviously watching and sharing.

Of course, numbers aren’t the point. We hope that it will switch on some light bulbs and make people think about changing their ways of working.  But it’s too early to say whether it has achieved this – ask me again in a year!

P&P: Popular it may be, but some people haven’t liked it, as evidenced by a few detractors on Pharmalot. Do those people have a point?

PS: The main objection seems to be a belief that we are poking fun at the pharma sales rep. And this is a group of people who are going through tough times. There is plenty of fear, diminishing returns and plenty of lay-offs within this group, and we’re kicking them while they’re down.

Laughing at others’ misfortune is certainly not our intention, nor do we want to rub people’s noses in it. The theme of the film was ‘evolution’, not ‘death’: we have used parody in an attempt to reduce or remove the ‘old style’ of rep from the face of the industry and make no apologies for communicating that in the most effective way we can think of. There are now plenty of examples of where a more mature focus on the differing types of customer and an individual level of communication has created great returns – for both the pharma company and patient. The changes within healthcare systems across the world provide an unprecedented opportunity to improve communication and rid this industry of its terrible reputation. But action, not sympathy, is required in order to make that happen.

P&P: What’s next for eyeforpharma?

PS: Well, connected to this film is the 10^th anniversary of our annual flagship event in Barcelona. This time we’re co-locating our eMarketing event with it, so we’ll have more than a thousand people in one space.

It’s interesting to me that whenever we’ve mentioned to the sales community that we’re bringing the online marketers to the same venue, they’ve welcomed this with open arms.

However, the opposite has been true of the online community. Their reaction has been either sheer ambivalence or more of a ‘what, those guys? What have they got to offer?’

For us, it’s clear that progress will only happen when both groups understand how to work together. And we’ve still got a fair bit of work to do in order to answer the question: ‘with 1000 pharma executives in one place, what together can we achieve?’ That’s the opportunity we have. Indeed, e would welcome input from anyone out there as to how to get the most out of this unique gathering. We may even let you take control!

Apart from that, we have a lot more initiatives in the pipeline. Some of them are even quite serious – for example we are currently running a mobile health competition which will really improve the lives of teenage cancer patients. It has backing from Livestrong and 9 other charities and we’re very excited about that.

P&P: And tell us… What will your next acting gig be?

PS: Hopefully none for a while! I hadn’t even intended to be in this one; clearly the camera crew decided I was the most Neanderthal-like and simply had to play the ‘alpha rep’. I guess it’s praise of a sort.

by DJ Edgerton (@wiltonbound)

The question seems almost nonsensical at first – your Twitter followers may be really outstanding people, but they’re not organic chemists or researchers. And your Facebook fans, while devoted, probably do not, generally speaking, know how to move a new drug through the FDA approval process.

Just the same, it’s a mistake to discount your social audiences as a source for insight and innovation. In fact, a wide range of category-leading companies do just that. While social media is not as planned or controlled as a focus group, there’s potential in polling the audience when it comes to research and development – and along the way you can even benefit the very people you’re polling.

Doing it right requires a three-step plan:

Understand what you want to accomplish. In this regard, social media is no different than traditional R&D research: Don’t ask existing or potential customers anything without a clear purpose behind “the ask.” What do you want to accomplish? Are you looking for feedback on a service (such as when consumers call into the customer care center) or improvement on a product or direction for a new advertising campaign? What about new products: Are you exploring the potential for one or looking at whether your customers have a need for a product that you have not thought of?

A solid roadmap will have goals covering what you hope to accomplish and clear indications of which social channels are – and are not – appropriate. Need to demo a product? You Tube makes sense. On the other hand, Twitter may be a better fit for simple questions requiring quick feedback. And tools like custom Facebook apps offer ways to bring customers and fans into the content creation process.

Be relevant in your questions and rigorous in your data collection. A solid roadmap lays out needs and expectations, but even the best plans can go astray if your research questions don’t balance your needs with the realities of social media, which often boil down to: Don’t be boring.

Tweets sending people to a 50-question survey or requests that Facebook followers sit through six sample commercials in search of the one they like best are unlikely to go anywhere. Instead, keep things short, clear and – most importantly – be ready to monitor and take feedback from the conversations that grow out of your public questions. They can be the source of tremendous insight.

Crunch the data and don’t leave the audience in the dark. One of the unique aspects of social media is that a lot of silos get knocked down – people have a great (and sometimes unreasonable) desire to peek behind the corporate curtain and know what’s going on. This is a powerful force and can jump-start your social-driven research – people love to be treated like insiders, and promising to give them a first peek at a new innovation, a new campaign or even just a slight change in how your company does something will motivate participation in your research.

The key is: You have to deliver on your promise. If you tell participants you’re working on a new way to talk about an established product and want their input, give them a peek before it’s rolled out to the public. Not doing so is bad form in the social landscape; promising to do it and then not delivering is an even bigger faux pas.

Whether it’s a one-drug boutique company or a global powerhouse, research and development is a constant part of pharma’s product and service lifecycles. While social media isn’t a substitute for formalized marketing research, it can be a powerful, low-cost augmentation to the toolbox.

Ceci Zak of Sanofi speaks to Alice An at Digital Pharma East, after her presentation on the focus on consumer-centric marketing in pharma.

What direction do you think this will take in 2012?